- Telehealth Visits
- Insurance plan information
Erik Levinsohn, MD
Psychiatry • Consultation Liaison Psychiatry- Telehealth Visits
- Insurance plan information
Erik Levinsohn, MD
Psychiatry • Consultation Liaison Psychiatry- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Consultation-Liaison Psychiatry - Subspecialty, American Board of Psychiatry and Neurology
- Psychiatry, American Board of Psychiatry and Neurology
Fellowship
- Consultation-Liaison Psychiatry, Boston University Orthopedic Sports Med Fellowship
Residency
- Psychiatry, Beth Israel Deaconess Medical Center GME
Degree
- MD, Yale University School of Medicine
My expertise
Specialties
- Psychiatry
- Consultation Liaison Psychiatry
Component Name: Provider Research Listing component built but no clinical trials or publications to display
Clinical Trials query: q=health_gateway_id_ss%3A%28%225029%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%225029%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.